# Vaccine Against Escherichia Coli Infection

> **NCT02289794** · PHASE1 · COMPLETED · sponsor: **GlycoVaxyn AG** · enrollment: 194 (actual)

## Conditions studied

- E.Coli Infections

## Interventions

- **BIOLOGICAL:** E.coli bioconjugate vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02289794
- **Lead sponsor:** GlycoVaxyn AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-09
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2016-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289794, "Vaccine Against Escherichia Coli Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02289794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*